StreetInsider.com News Articles

Form 8-K Allarity Therapeutics, For: May 27

Tue, 02 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260602/26593100.html

Form 8-K Allarity Therapeutics, For: May 27

Tue, 02 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260602/26593100.html

Allarity Therapeutics (ALLR) Misses Q1 EPS by 17c

Mon, 18 May 2026 06:46:54 -0400

Allarity Therapeutics (NASDAQ: ALLR) reported Q1 EPS of ($0.17).

For earnings history and earnings-related data on Allarity Therapeutics (ALLR) click here.

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Fri, 15 May 2026 16:30:00 -0400

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer

- Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP^® companion diagnostic

- Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026

TARPON SPRINGS, Fla., MAY 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Fri, 15 May 2026 16:30:00 -0400

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Fri, 15 May 2026 16:30:00 -0400

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Fri, 15 May 2026 16:30:00 -0400

Form 10-Q Allarity Therapeutics, For: Mar 31

Fri, 15 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26504953.html

Form 10-Q Allarity Therapeutics, For: Mar 31

Fri, 15 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26504953.html

Form 4 Allarity Therapeutics, For: Jan 28 Filed by: Jensen Thomas

Thu, 14 May 2026 11:49:00 -0400

si-local-file:///var/storage/secattach/20260514/26492453.html

Form 4 Allarity Therapeutics, For: Jan 28 Filed by: Jensen Thomas

Thu, 14 May 2026 11:49:00 -0400

si-local-file:///var/storage/secattach/20260514/26492453.html

Form 4 Allarity Therapeutics, For: Jan 28 Filed by: Hoeiland Jesper

Mon, 11 May 2026 15:22:00 -0400

si-local-file:///var/storage/secattach/20260511/26468448.html

Form 4 Allarity Therapeutics, For: Jan 28 Filed by: Hoeiland Jesper

Mon, 11 May 2026 15:22:00 -0400

si-local-file:///var/storage/secattach/20260511/26468448.html

Form 3 Allarity Therapeutics, For: Jun 10 Filed by: Hoeiland Jesper

Mon, 11 May 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260511/26468441.html

Form 3 Allarity Therapeutics, For: Jun 10 Filed by: Hoeiland Jesper

Mon, 11 May 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260511/26468441.html

Form 8-K Allarity Therapeutics, For: May 08

Fri, 08 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260508/26462595.html

Form 8-K Allarity Therapeutics, For: May 08

Fri, 08 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260508/26462595.html

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Fri, 08 May 2026 08:45:00 -0400

TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden.

Presentation Details:

Event: Precision Medicine Forum Europe 2026
Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical Trials
Track: Oncology
Date: Monday, May 11, 2026
Time: 10:20–10:40 CEST

Mr. Jensen will discuss stenoparib’s dual

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Fri, 08 May 2026 08:45:00 -0400

Mr. Jensen will discuss stenoparib’s dual

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Fri, 08 May 2026 08:45:00 -0400

Mr. Jensen will discuss stenoparib’s dual

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Fri, 08 May 2026 08:45:00 -0400

Mr. Jensen will discuss stenoparib’s dual

Form 4 Allarity Therapeutics, For: Jan 28 Filed by: McLaughlin Gerald W.

Thu, 07 May 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26455672.html

Form 4 Allarity Therapeutics, For: Jan 28 Filed by: McLaughlin Gerald W.

Thu, 07 May 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26455672.html

Form 8-K Allarity Therapeutics, For: May 05

Wed, 06 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260506/26439568.html

Form 8-K Allarity Therapeutics, For: May 05

Wed, 06 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260506/26439568.html